etanidazole has been researched along with Benign Neoplasms, Brain in 14 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 9.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| "To report the survival results from a previous Phase I study of etanidazole (ETA) and radiotherapy in patients with glioblastoma multiforme (GBM n = 50) or anaplastic astrocytoma (AA n = 19) and examine survival according to age, Karnofsky performance status (KPS), and implant status." | 5.08 | Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. ( Alexander, E; Black, PM; Chang, EL; Coleman, CN; Loeffler, JS; Riese, NE; Wen, PY, 1998) |
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 5.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| "Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation." | 2.73 | A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02). ( Cmelak, AJ; Drzymala, RE; Loeffler, J; Shaw, E; Souhami, L; Wasserman, TH; Won, M, 2008) |
| "Tissues from six human brain tumors were assessed." | 1.35 | Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. ( Dilling, T; Evans, SM; Hahn, SM; Jenkins, KW; Jenkins, WT; Judkins, A; Judy, KD; Koch, CJ; Schrlau, A, 2008) |
| "Human brain tumors are dominated by oxic to moderately hypoxic cells." | 1.32 | Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. ( Collins, R; Dunphy, I; Evans, SM; Geoerger, B; Hahn, SM; Jenkins, K; Jenkins, WT; Judkins, AR; Judy, KD; Koch, CJ; Nelson, PT; Phillips, P; Stevens, CW; Wileyto, EP, 2004) |
| "Etanidazole was developed as an oxygen-mimetic radiosensitizer less lipophilic than misonidazole." | 1.28 | Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas. ( Alexander, E; Buswell, L; Coleman, CN; Hurwitz, SJ; Kramer, RA; Loeffler, JS; Neben, TY; Riese, N; Shargel, L, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, SM | 5 |
| Jenkins, KW | 1 |
| Jenkins, WT | 3 |
| Dilling, T | 1 |
| Judy, KD | 4 |
| Schrlau, A | 1 |
| Judkins, A | 1 |
| Hahn, SM | 4 |
| Koch, CJ | 5 |
| Scheuermann, JS | 1 |
| Divgi, C | 1 |
| Kachur, AV | 1 |
| Freifelder, R | 1 |
| Reddin, JS | 1 |
| Karp, J | 1 |
| Stubbs, JB | 1 |
| Driesbaugh, J | 1 |
| Smith, D | 1 |
| Prendergast, S | 1 |
| Tan, WH | 2 |
| Wang, F | 1 |
| Lee, T | 2 |
| Wang, CH | 2 |
| Dunphy, I | 2 |
| Nelson, PT | 2 |
| Collins, R | 1 |
| Wileyto, EP | 1 |
| Jenkins, K | 2 |
| Stevens, CW | 1 |
| Judkins, AR | 1 |
| Phillips, P | 1 |
| Geoerger, B | 1 |
| Hwang, WT | 1 |
| Lustig, RA | 1 |
| Magarelli, DP | 1 |
| Collins, RA | 1 |
| Grady, MS | 1 |
| Vordermark, D | 1 |
| Drzymala, RE | 1 |
| Wasserman, TH | 1 |
| Won, M | 1 |
| Shaw, E | 1 |
| Cmelak, AJ | 1 |
| Loeffler, J | 1 |
| Souhami, L | 1 |
| Riese, NE | 2 |
| Loeffler, JS | 3 |
| Wen, P | 1 |
| Alexander, E | 3 |
| Black, PM | 2 |
| Coleman, CN | 3 |
| Chang, EL | 1 |
| Wen, PY | 1 |
| Hurwitz, SJ | 1 |
| Riese, N | 1 |
| Buswell, L | 1 |
| Neben, TY | 1 |
| Shargel, L | 1 |
| Kramer, RA | 1 |
| Wong, KH | 1 |
| Wallen, CA | 1 |
| Wheeler, KT | 1 |
| Newman, HF | 1 |
| Bleehen, NM | 1 |
| Ward, R | 1 |
| Workman, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer[NCT01881451] | 5 participants (Actual) | Observational | 2013-08-31 | Terminated (stopped due to Due to slow accrual and access to the study drug.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for etanidazole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Topics: Biological Transport; Brain Neoplasms; Cell Hypoxia; Etanidazole; Female; Fluorine Radioisotopes; Gl | 2010 |
A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Etanidazole; Humans; Neoplasm Recurrence, Local; | 2008 |
A phase I study of etanidazole and radiotherapy in malignant glioma.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Etanidazole; Female; Glioma; Humans; Male; Middle Aged | 1994 |
Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Etanidazole; Feasib | 1998 |
10 other studies available for etanidazole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Animals; Brain Neoplasms; Etanidazole; Gliob | 2008 |
In regard to Brown et al. (Int J Radiat Oncol Biol Phys 2010;78:323-327).
Topics: Brain Neoplasms; Cell Hypoxia; Etanidazole; Humans; Neoplasms; Radiation-Sensitizing Agents | 2011 |
Computer simulation of the delivery of etanidazole to brain tumor from PLGA wafers: comparison between linear and double burst release systems.
Topics: Animals; Brain Neoplasms; Computer Simulation; Drug Delivery Systems; Drug Implants; Etanidazole; Hu | 2003 |
Simulation of intratumoral release of Etanidazole: effects of the size of surgical opening.
Topics: Biological Availability; Brain Neoplasms; Computer Simulation; Drug Delivery Systems; Edema; Etanida | 2003 |
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Electrodes; Etanidazole; Humans; Hydrocarbons, Fluorinat | 2004 |
Hypoxia is important in the biology and aggression of human glial brain tumors.
Topics: Aged; Brain Neoplasms; Electrodes; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypoxia; | 2004 |
Significance of hypoxia in malignant glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.
Topics: Antineoplastic Agents; Brain Neoplasms; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypo | 2005 |
Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas.
Topics: Brain Neoplasms; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intrave | 1992 |
2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1991 |
Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Brain Neoplasms; Drug Therapy, Combination; Etanidazole; Glioblastoma; Humans; Nitroimidazoles; Radi | 1988 |